RMX3001 (original product code in Korea is DHP107, registered name Liporaxel) is an oral preparation of paclitaxel jointly developed by DAEHWA Pharmaceuticals and the Korea Institute of Science and Technology (KIST). Among them, paclitaxel is dissolved in "DH-LASED" (DaeHwa - lipid-based self-emulsifying drug delivery technology, a patented technology of DAEHWA Pharmaceutical Co.). Using this technology, the active ingredient paclitaxel is delivered through lipids, solving the main difficulty causing the low oral bioavailability of paclitaxel.
RMX3001 (foreign code: DHP107) has successfully obtained marketing approval from the Korean Food and Drug Administration (MFDS) on September 9, 2016. The indications are advanced and metastatic or locally recurrent gastric cancer. It is The world's first oral paclitaxel product successfully developed and approved for marketing. Patients in need can consult or purchase through regular overseas medical platforms (such as Hong Kong Magikang Medical Center, etc.).
RMX3001 (foreign code: DHP107)'s key phase III gastric cancer clinical trial in South Korea shows that compared with paclitaxel injection, it can significantly reduce the occurrence of adverse reactions in patients, such as "peripheral neuropathy" and "anaphylaxis" ”, “Alopecia”, “Myalgia”. In addition, oral administration also avoids adverse reactions such as injection extravasation and phlebitis that may be caused by intravenous injection.